



# Kabra Drugs Limited

CIN NO : L02423MP1989PLC005438

Corp. Off : No.3, 2nd Floor, Swaminathan Street, West Mambalam, Chennai - 600 033.

---

Date: 30<sup>th</sup> May 2026

To,  
BSE Limited  
Phiroze Jeejeebhoy Towers  
21<sup>st</sup> Floor, Dalal Street  
Mumbai – 400001

**BSE Scrip Code: 524322**

**Subject: Press Release on audited Financial Results for Quarter and Year ended on 31st March, 2026**

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith Press Release on audited Financial Results for Quarter and Year ended on 31st March, 2026.

The above can also be accessed on the website of the Company at [www.kabradrugs.com](http://www.kabradrugs.com)

Kindly take the aforesaid information on record and oblige.

Thanking you,

Yours sincerely,

**For Kabra Drugs Limited**

**Kuniamuthur Nanjappan Anand**

**Director**

**DIN: 03230186**





## Kabra Drugs Limited Enters a Decisive New Era of Growth with Exceptional FY26 Financial Performance

**Total Income at ₹93.23 Crore, up 14,463.06% YoY | EBITDA & PAT Turn Positive**

**Chennai, May 30, 2026** – Kabra Drugs Limited, (BSE: KABRADG | INE323K01017) a research-driven pharmaceutical company focused on specialty formulations, injectables, and APIs, announced its audited financial results for Q4 FY26 and FY26, along with strategic expansion initiatives in pharmaceutical manufacturing, marketing, AI-led defence technologies, and advanced manufacturing capabilities.

### Q4 FY26 Key Financial Highlights

Particulars (₹ Lakhs)	Q4 FY26	Q4 FY25	YoY Growth
Total Income	3,551.91	64.02	5,448.13%
EBITDA	145.24	39.81	264.83%
PAT	106.33	39.36	170.15%
EPS (₹)	0.45	0.21	114.29%

### FY26 Key Financial Highlights

Particulars (₹ Lakhs)	FY26	FY25	YoY Growth
Total Income	9,323.27	64.02	14,463.06%
EBITDA	582.18	(107.78)	Turn Positive
PAT	495.98	(108.56)	Turn Positive
EPS (₹)	2.09	(0.99)	Turn Positive

## Future Business Outlook & Expansion Strategy

### 1. Pharmaceutical Manufacturing & Marketing Expansion

- Expansion of the Company's branded generic & generic pharmaceutical manufacturing and marketing business.
- Expansion to be executed in phases through strategic channel partners arranged by "Mr. Franchise".
- Phase 1 will focus on strengthening the Company's presence across South India.

### 2. Defence & AI Expansion

- Assessed strategic opportunities in AI-led defence manufacturing and advanced technology-driven sectors.
- Company to initiate DGFT approval process for obtaining SCOMET License.
- AI & Defence Technology R&D facility to be established at Cactus TECCI Park, Chennai.

### 3. Strategic Outlook

- Pharma expansion to strengthen presence in high-growth therapeutic markets and improve healthcare access.
- AI & defence initiative aims to position the Company in advanced manufacturing and national security technologies.

## About Kabra Drugs Limited

Kabra Drugs Limited (Kabra Drugs) is a research-driven pharmaceutical company focused on specialty formulations, injectables, and APIs. Founded with the vision of making quality healthcare science-driven and accessible, the Company is committed to delivering safe, effective, and globally competitive pharmaceutical solutions.

Backed by WHO-GMP aligned systems, advanced manufacturing capabilities, and innovation-led processes, Kabra Drugs continues to strengthen its presence across key therapeutic areas while maintaining a strong focus on quality, integrity, and responsible growth.

## Commentary From The Management

**Commenting on the Company's Q4 FY26 and FY26 financial performance and strategic progress, Mr. N. Aravind, Managing Director of Kabra Drugs Limited, stated:**

"FY26 was the year Kabra Drugs Limited changed the narrative. What began as a phase of rebuilding has now evolved into a period of decisive execution, accelerated growth, and strategic transformation.

The scale of our turnaround is reflected in the numbers, FY26 Total Income stood at ₹93.23 crore, delivering an exceptional YoY growth of 14,463.06%, while EBITDA and PAT stood at ₹5.82 crore and ₹4.96 crore respectively, compared to losses in the previous financial year.

The momentum strengthened further in Q4 FY26, where Total Income rose to ₹35.52 crore, registering a remarkable YoY growth of 5,448.13%. EBITDA grew by 264.83% YoY to ₹1.45 crore, while PAT increased by 170.15% YoY to ₹1.06 crore, reflecting sharper execution, improving operational discipline, and stronger business fundamentals.

At Kabra Drugs, we are not merely scaling operations, we are building a future-ready pharmaceutical platform driven by innovation, quality, and strategic expansion. Our focus on specialty formulations, injectables, and APIs, combined with disciplined execution and manufacturing excellence, continues to strengthen the foundation of the business.

As we move forward, the Company remains committed to expanding its pharmaceutical manufacturing and marketing presence across high-growth markets, while simultaneously exploring opportunities in AI-led defence and advanced manufacturing technologies as part of our long-term strategic vision.

FY26 was not about survival. It was about resurgence. From losses to profitability and from limited scale to accelerated growth, Kabra Drugs Limited has emerged with renewed strength, sharper ambition, and a far more formidable vision for the future."

**Note:** The following short forms have been used in this document — AI (Artificial Intelligence), DGFT (Directorate General of Foreign Trade), SCOMET (Special Chemicals, Organisms, Materials, Equipment and Technologies), R&D (Research and Development), APIs (Active Pharmaceutical Ingredients), WHO-GMP (World Health Organization – Good Manufacturing Practices).

## Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For Further Information Please Contact Corporate Communication Advisor



*AKMIL Strategic Advisors Private Limited*  
*Mr. Milind Apte – Director*  
*milind@akmiladvisors.com*  
*+91 98209 41925*  
*www.akmiladvisors.com*